Fujisawa, Carlsson Research Conclude Licensing Agreement

Fujisawa Pharmaceutical has singed a licensing agreement with Carlsson Research, a Swedish pharmaceutical R&D company that has developed ACR-16, a new type of antipsychotic agent. Under the terms of the agreement, Fujisawa is granted the exclusive rights to develop, manufacture and sell ACR-16 all over the world. ACR-16, which can stabilize the level of the dopamine activity, is a promising agent for the treatment of schizophrenia and neuropsychiatric disorders like ADHD, Huntington's disease, Parkinson's disease and dementia.

Japan Corporate News (http://www.japancorp.net/Article.Asp?Art_ID=9350)